Cerebral capillaries constitute the blood-brain barrier. Studies of specific receptors (neurotransmitters or hormones) located on this structure can be performed by means of radioligand-binding techniques on isolated brain microvessels.
58 fmol/mg of protein. The binding of 125I-labeled ANF to brain microvessels is specific, reversible, and time dependent, as is shown by association-dissociation experiments. The demonstration of specific ANF-binding sites on brain microvessels supposes a physiological role of ANF on brain microvasculature. The coexistence of ANF and angiotensin II receptors on this cerebrovascular tissue suggests that the two circulating peptides may act as mutual antagonists in the regulation of brain microcirculation and/or blood-brain barrier function. microcirculation and/or the permeability of the blood-brain barrier.
MATERIALS AND METHODS
Materials. The nomenclature of atrial natriuretic peptides is based on the sequence of the propeptide containing 126 amino acids (rat y-ANF) deduced from the rat DNA sequence (9) (10) (11) . Synthetic and biologically active rat ANF used in our study has the following sequence of 28 amino acids from Ser-99 to Tyr-126:
NH2-Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg
S-S
Ile-Gly-Ala-Glu-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-COOH . Mammalian atria contain different peptides, including the atrial natriuretic factor (ANF), that possess potent diuretic, natriuretic, and vasoactive properties (1, 2) . ANF is released into the general circulation and has been proposed to be actively involved in blood-pressure regulation and fluid homeostasis as an antagonist of the renin-angiotensin (Ang) system through receptor-mediated actions in the kidney (3), vascular tissues (4), adrenal glands (5) , and brain (6) . In the brain, binding sites for ANF have been characterized in specific areas involved in blood-pressure control, such as the subfornical organ (7)-a circumventricular structure that lacks the tight capillary endothelial junctions of the blood-brain barrier and, therefore, is exposed to circulating peptides. Recently, specific binding sites for Ang II have been described in brain microvessels (8) gm) and washed extensively with Ringer's solution. The filtrate was centrifuged at 1100 x g for 10 min, and the pellet was resuspended in Ringer's solution modified to contain 30% bovine serum albumin and then submitted three times to albumin floatation by centrifugation at 1100 x g for 20 min. The resulting pellets containing brain microvessels were suspended in the original buffer (1% bovine serum albumin), and the suspension was passed through columns of glass beads (diameter, 0.2-0.5 mm) and washed extensively to eliminate nuclei and erythrocytes. Microvessels attached on the glass beads were released by gentle agitation in Ringer's solution, collected, and washed three times by dispersion and centrifugation in the same cold buffer used for binding assay. Purity and homogeneity of brain microvessels were assessed by phase-contrast microscopy and by enzymatic-activity Abbreviations: ANF, atrial natriuretic factor; Ang II, angiotensin II. *To whom reprint requests should be addressed.
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Binding assay of ANF. Fresh suspensions of brain microvessels were prepared by homogenization in Tris HCl buffer (50 mM Tris HCl, pH 7.4/100 mM NaCl/5 mM MgCl2) containing 0.4% bovine serum albumin, 0.02% bacitracin, and 0.5 mg/liter of phenylmethylsulfonyl fluoride (homogenization buffer). '25I-ANF binding to brain microvessels was carried out for 1 hr at 0-4°C in a total volume of 0.3 ml. Nonspecific binding was determined in the presence of 1 ,uM of rat ANF. Specific '25I-ANF binding was calculated by subtracting nonspecific binding from total binding. 1251I-ANF and unlabeled ligand, when used, were combined in the assay tube, followed by the addition of the suspension of brain microvessels (60-130 pg of protein per tube) to initiate the binding reaction. Binding was allowed to proceed for 1 hr at 0-4°C to equilibrium. Bound 1251I-ANF was separated from free 1"I-ANF by immediate filtration through Whatman GF/C glass fiber filters under vacuum. The reaction tube and the filter were washed twice with 10 ml of cold buffer. The filters were assayed for radioactivity in a LKB y counter with 70% efficiency.
Protein concentrations were determined by the Bradford method (13) 
RESULTS
The purity of the bovine cerebral microvessel preparations was checked by phase-contrast microscopy ( Fig. 1) . The preparations appeared free from neuronal and glial elements and consisted of networks of microvessels, mostly capillaries (diameter, 5-15 ,um) with some small venules and arterioles One unit of y-glutamyl transpeptidase is defined as that amount of activity that will liberate 1 nmol of p-nitroaniline per min at 250C (Sigma kit). One unit of alkaline phosphatase will transform 1 ,umol of p-nitrophenyl phosphate per min at 30'C (Sigma kit). *Numbers in parentheses = n.
and occasionally trapped blood cells. The purity of the preparation was confirmed by enzymatic assays of alkaline phosphatase and y-glutamyl transpeptidase, which are specifically located on brain microvessels (17, 18) . The measured activities of t-glutamyl transpeptidase and alkaline phosphatase were, respectively, 24 and 27 times higher in the microvessels than in the grey-matter homogenate, indicating that the preparations were highly purified (Table 1) . I251-ANF was found to bind specifically to bovine brain microvessels. The results of a typical experiment with saturability ofbinding, which was replicated four times, are shown in Fig. 2 . Concentrations of 125I-ANF ranged from 0.01 to 0.6 nM. Scatchard analysis of the binding to cerebral microvessels revealed a single class of binding sites of high affinity with a Kd value and a maximum binding of 0.11 nM and 58 fmol/mg of protein, respectively (Fig. 3) . Binding was a linear function of protein concentration over the range of 25-150 ,g per tube.
In a second set of experiments, the time course of association and dissociation of a low concentration (0.15 nM) of 125I-ANF to brain microvessels was studied (Fig. 4) . It was observed that 125I-ANF displayed a rate of association with a half-life of about 5 was shown by dissociation with the addition of native ANF to a final concentration of 1 ,uM (Fig. 4) .
The reversibility and the specificity of ANF binding to cerebral microvessels were also assessed by displacing 125I_ ANF binding by unlabeled ANF and by structurally unrelated peptides. '251-ANF, whereas nonrelated peptide hormones do not significantly displace radioactive ANF. The observed dissociation constant of 125I-ANF to brain microvessels corresponds to a high-affinity site similar to those obtained in other vascular tissues for larger vessels such as rabbit aorta (3), rat aorta (21) , rat mesenteric arteries, and renal arteries (5) and in bovine aortic smooth muscle and endothelial cells (22) .
The ANF high-affinity receptor sites possess binding capacity depending upon the origin of the tissue: from low levels (10 fmol/mg of protein) for tissues weakly responsive to ANF to high levels (100-200 fmol/mg of protein) for tissues highly responsive to ANF. An beds including capillaries after intravenous injection of 1251_ ANF into the general circulation.
At present, no physiological effect of ANF has been demonstrated on brain microvasculature. Our report on ANF receptor binding sites on bovine cerebral microvessels suggests a physiological role of ANF at this level. The coexistence of both ANF-receptor and Ang II-receptor binding sites in cerebral microvessels led us to suggest that the two systems, which seem to be highly involved in an opposite fashion in the regulation of blood pressure and fluid homeostasis, can also act as mutual antagonists in the control of brain microcirculation and may also have important implications in blood-brain barrier function. In fact, much data show that brain microvessel function and morphology are altered during hypertension. Cerebral capillary injuries such as increased diameter, endothelial degeneration, and deposition of collagen are reported in experimental hypertensive monkeys and in humans (24, 25) . Physiological and biochemical evidence indicates that hypertension causes an increase in the permeability of the blood-brain barrier. Extravasation of protein markers and cerebral edema because of a breakdown of the blood-brain barrier have been reported during acute elevation of systolic blood pressure and chronic hypertension (25, 26) . Similar disturbances in the permeability of the blood-brain barrier can be induced by i.v. injection of Ang II (27) .
Recent anatomical, physiological, and biochemical studies have provided evidence for a neuronal control of the blood-brain barrier (28) , particularly by the adrenergic system (29) . The presence of ANF as well as Ang II receptors on brain microvessels supports the hypothesis that circulating hormones also like ANF and Ang II may cooperate with neurogenic factors in the control of the blood-brain barrier functions. Alterations of these peptidergic systems may have important implications in various cerebrovascular disorders.
